B.Riley Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)

March 20, 2026 4:50 AM

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found